Related Experiment Video

Updated: Jul 31, 2026

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

Mechanism of benefit of negative inotropes in obstructive hypertrophic cardiomyopathy

M V Sherrid1, G Pearle, D Z Gunsburg

  • 1Division of Cardiology, St. Luke's-Roosevelt Hospital Center, Columbia University, College of Physicians and Surgeons, New York, NY 10019, USA. m.sherrid@mindspring.com

Circulation
|January 27, 1998
PubMed

Insights

Medications for hypertrophic cardiomyopathy (HCM) reduce obstruction by slowing left ventricular ejection acceleration. This prevents mitral-septal contact, decreasing the pressure gradient.

Area of Science:

  • Cardiology
  • Biomedical Engineering
  • Pharmacology

Background:

  • Hypertrophic cardiomyopathy (HCM) is often treated with drugs that reduce contractility.
  • The precise mechanism by which these drugs alleviate obstruction in HCM remains unclear.

Purpose of the Study:

  • To investigate the hemodynamic mechanism by which negative inotropic drugs reduce left ventricular outflow tract obstruction in patients with obstructive HCM.

Main Methods:

  • Utilized M-mode, 2D, and pulsed Doppler echocardiography in 11 obstructive HCM patients.
  • Analyzed left ventricular ejection dynamics before and after successful medical obstruction elimination.

Main Results:

  • Treatment significantly slowed left ventricular ejection acceleration (34%) and prolonged ejection times.
  • Peak ejection velocity remained unchanged, but its timing shifted later in systole.
  • No changes in mitral-septal distance indicated preserved anatomy.

Conclusions:

  • Medical therapy for obstructive HCM works by decreasing left ventricular ejection acceleration.
  • Slower acceleration reduces mitral leaflet impact and delays mitral-septal contact.
  • This mechanism leads to a reduced pressure gradient across the left ventricular outflow tract.
Abstract

More Related Videos

Studying Left Ventricular Reverse Remodeling by Aortic Debanding in Rodents07:26

Studying Left Ventricular Reverse Remodeling by Aortic Debanding in Rodents

Published on: July 14, 2021

Magnetic Adjustment of Afterload in Engineered Heart Tissues09:40

Magnetic Adjustment of Afterload in Engineered Heart Tissues

Published on: May 5, 2020

Related Concept Videos

Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...